Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Meeting with management

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on May 06, 2022 11:49am

102 Views

Post# 34662356

RE:RE:RE:RE:RE:Meeting with management

So tell me what being in line with .......means.

CreatingApe wrote: Once again it seems you are trying to get Spceo to stop sharing with us. And again trying to possibly get the company in which you are invested in trouble. Why. From what I remember they have made that same statement in multiple calls and press releases already. "Closely in line with pre clinical" Obviously they didn't elaborate to a few big shareholders about efficacy weeks before we probably get a press release with details about the trial.

<< Previous

Bullboard Posts

Next >>

New Found Gold begins surface trenching at Queensway